Details of the Drug

General Information of Drug (ID: DMMEJ6K)

Drug Name
Zilovertamab
Indication
Disease Entry ICD 11 Status REF
Mantle cell lymphoma 2A85.5 Phase 2 [1]
Prostate cancer 2C82.0 Phase 1 [2]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D8P1KS
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neurotrophic tyrosine kinase ROR1 (ROR1) TTDEJAU ROR1_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03088878) A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05156905) A Phase 1b Trial Investigating Docetaxel Combined With Cirmtuzumab in Patients With Metastatic Castration Resistant Prostate Cancer. U.S.National Institutes of Health.
3 The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022 Apr 11;14(4):837.